The Safety and Feasibility of Neoadjuvant Camrelizumab With Palbociclib for the Treatment of Resectable Esophageal Squamous Cell CarcinomaA Phase 1 Trial

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

26 Nov 2024 The protocol has been amended to increase in drug dose Palbociclib (150 mg) Four weeks is a cycle and it will be given for four cycles..
15 Nov 2024 Planned primary completion date changed from 31 Oct 2024 to 31 Oct 2025.
28 Oct 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com